OraSure Technologies, Inc.

Equities

OSUR

US68554V1089

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 16:53:25 26/06/2024 BST 5-day change 1st Jan Change
4.215 USD -0.12% Intraday chart for OraSure Technologies, Inc. -7.38% -48.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from S&P 600 Health Care CI
OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from S&P 1000 CI
OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from S&P 600 CI
OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from S&P Composite 1500 CI
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 MT
JPMorgan Adjusts OraSure Technologies Price Target to $6 From $7, Maintains Neutral Rating MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q1 Revenue $54.1M, vs. Street Est of $52.3M MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q1 EPS $0.04, vs. Street Est of $0.03 MT
Transcript : OraSure Technologies, Inc., Q1 2024 Earnings Call, May 08, 2024
OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024 CI
OraSure Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : OraSure Technologies, Inc., 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q4 Revenue $75.9M, vs. Street Est of $74.3M MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q4 EPS $0.22, vs. Street Est of $0.11 MT
OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 CI
OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter 2024 CI
OraSure Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
OraSure Technologies, Inc. Seeks M&A CI
OraSure Technologies Leads Series B Funding, Strikes Distribution Rights With Sapphiros MT
Transcript : OraSure Technologies, Inc. - Special Call
Orasure Technologies, Inc. Secures Strategic Distribution Rights with Sapphiros CI
Sapphiros AI Bio LLC announced that it has received $30 million in funding from OraSure Technologies, Inc. CI
Citigroup Adjusts OraSure Technologies Price Target to $9 From $7, Maintains Buy Rating MT
Tranche Update on OraSure Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2008. CI
OraSure Technologies to Seek Acquisitions CI
Chart OraSure Technologies, Inc.
More charts
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.22 USD
Average target price
6.625 USD
Spread / Average Target
+56.99%
Consensus
  1. Stock Market
  2. Equities
  3. OSUR Stock
  4. News OraSure Technologies, Inc.
  5. Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q1 Revenue $54.1M, vs. Street Est of $52.3M